Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial von Hida, Toyoaki, MD, Nokihara, Hiroshi, MD, Kondo, Masashi, MD, Kim, Young Hak, MD, Azuma, Koichi, MD, Seto, Takashi, MD, Takiguchi, Yuichi, Prof, Nishio, Makoto, MD, Yoshioka, Hiroshige, MD, Imamura, Fumio, MD, Hotta, Katsuyuki, Prof, Watanabe, Satoshi, MD, Goto, Koichi, MD, Satouchi, Miyako, MD, Kozuki, Toshiyuki, MD, Shukuya, Takehito, MD, Nakagawa, Kazuhiko, Prof, Mitsudomi, Tetsuya, Prof, Yamamoto, Nobuyuki, Prof, Asakawa, Takashi, PhD, Asabe, Ryoichi, MS, Tanaka, Tomohiro, MS, Tamura, Tomohide, Dr

Volltext

Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial von Takahashi, Toshiaki, MD, Yamanaka, Takeharu, Prof, Seto, Takashi, MD, Harada, Hideyuki, MD, Nokihara, Hiroshi, MD, Saka, Hideo, MD, Nishio, Makoto, MD, Kaneda, Hiroyasu, MD, Takayama, Koichi, MD, Ishimoto, Osamu, MD, Takeda, Koji, MD, Yoshioka, Hiroshige, MD, Tachihara, Motoko, MD, Sakai, Hiroshi, MD, Goto, Koichi, MD, Yamamoto, Nobuyuki, Prof

Volltext

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, rand... von Seto, Takashi, MD, Kato, Terufumi, MD, Nishio, Makoto, MD, Goto, Koichi, MD, Atagi, Shinji, MD, Hosomi, Yukio, MD, Yamamoto, Noboru, MD, Hida, Toyoaki, MD, Maemondo, Makoto, MD, Nakagawa, Kazuhiko, Prof, Nagase, Seisuke, MD, Okamoto, Isamu, MD, Yamanaka, Takeharu, PhD, Tajima, Kosei, MSc, Harada, Ryosuke, BS, Fukuoka, Masahiro, MD, Yamamoto, Nobuyuki, Prof

Volltext

Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer von Nakagawa, Kazuhiko, Hida, Toyoaki, Nokihara, Hiroshi, Morise, Masahiro, Azuma, Koichi, Kim, Young Hak, Seto, Takashi, Takiguchi, Yuichi, Nishio, Makoto, Yoshioka, Hiroshige, Kumagai, Toru, Hotta, Katsuyuki, Watanabe, Satoshi, Goto, Koichi, Satouchi, Miyako, Kozuki, Toshiyuki, Koyama, Ryo, Mitsudomi, Tetsuya, Yamamoto, Nobuyuki, Asakawa, Takashi, Hayashi, Morihiko, Hasegawa, Wakako, Tamura, Tomohide

Volltext

Crizotinib Can Overcome Acquired Resistance to CH5424802: Is Amplification of the MET Gene a Key Factor? von Gouji, Toyokawa, Takashi, Seto, Mitsuhiro, Takenoyama, Yukito, Ichinose

Volltext

Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study von Katsuya, Yuki, Horinouchi, Hidehito, Seto, Takashi, Umemura, Shigeki, Hosomi, Yukio, Satouchi, Miyako, Nishio, Makoto, Kozuki, Toshiyuki, Hida, Toyoaki, Sukigara, Tamie, Nakamura, Kenichi, Kuchiba, Aya, Ohe, Yuichiro

Volltext

Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer von Kenmotsu, Hirotsugu, Yamamoto, Nobuyuki, Yamanaka, Takeharu, Yoshiya, Katsuo, Takahashi, Toshiaki, Ueno, Tsuyoshi, Goto, Koichi, Daga, Haruko, Ikeda, Norihiko, Sugio, Kenji, Seto, Takashi, Toyooka, Shinichi, Date, Hiroshi, Mitsudomi, Tetsuya, Okamoto, Isamu, Yokoi, Kohei, Saka, Hideo, Okamoto, Hiroaki, Takiguchi, Yuichi, Tsuboi, Masahiro

Volltext

Vandetanib in patients with previously treated RET -rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial von Yoh, Kiyotaka, Dr, Seto, Takashi, MD, Satouchi, Miyako, MD, Nishio, Makoto, MD, Yamamoto, Noboru, MD, Murakami, Haruyasu, MD, Nogami, Naoyuki, MD, Matsumoto, Shingo, MD, Kohno, Takashi, PhD, Tsuta, Koji, Prof, Tsuchihara, Katsuya, MD, Ishii, Genichiro, MD, Nomura, Shogo, MSc, Sato, Akihiro, MD, Ohtsu, Atsushi, MD, Ohe, Yuichiro, MD, Goto, Koichi, MD

Volltext

CH5424802 (RO5424802) for patients with ALK -rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study von Seto, Takashi, MD, Kiura, Katsuyuki, Prof, Nishio, Makoto, MD, Nakagawa, Kazuhiko, Prof, Maemondo, Makoto, MD, Inoue, Akira, MD, Hida, Toyoaki, MD, Yamamoto, Nobuyuki, MD, Yoshioka, Hiroshige, MD, Harada, Masao, MD, Ohe, Yuichiro, MD, Nogami, Naoyuki, MD, Takeuchi, Kengo, MD, Shimada, Tadashi, MS, Tanaka, Tomohiro, MS, Tamura, Tomohide, Dr

Volltext

Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non‐small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX‐Lung 3 von Kato, Terufumi, Yoshioka, Hiroshige, Okamoto, Isamu, Yokoyama, Akira, Hida, Toyoaki, Seto, Takashi, Kiura, Katsuyuki, Massey, Dan, Seki, Yoko, Yamamoto, Nobuyuki

Volltext

Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date von Akamine, Takaki, Toyokawa, Gouji, Tagawa, Tetsuzo, Seto, Takashi

Volltext

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, rando... von Mitsudomi, Tetsuya, Dr, Morita, Satoshi, Prof, Yatabe, Yasushi, MD, Negoro, Shunichi, MD, Okamoto, Isamu, MD, Tsurutani, Junji, MD, Seto, Takashi, MD, Satouchi, Miyako, MD, Tada, Hirohito, MD, Hirashima, Tomonori, MD, Asami, Kazuhiro, MD, Katakami, Nobuyuki, MD, Takada, Minoru, Prof, Yoshioka, Hiroshige, MD, Shibata, Kazuhiko, MD, Kudoh, Shinzoh, MD, Shimizu, Eiji, Prof, Saito, Hiroshi, MD, Toyooka, Shinichi, MD, Nakagawa, Kazuhiko, Prof, Fukuoka, Masahiro, Prof

Volltext

The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV von Akamatsu, Hiroaki, Ninomiya, Kiichiro, Kenmotsu, Hirotsugu, Morise, Masahiro, Daga, Haruko, Goto, Yasushi, Kozuki, Toshiyuki, Miura, Satoru, Sasaki, Takaaki, Tamiya, Akihiro, Teraoka, Shunsuke, Tsubata, Yukari, Yoshioka, Hiroshige, Hattori, Yoshihiro, Imamura, Chiyo K., Katsuya, Yuki, Matsui, Reiko, Minegishi, Yuji, Mizugaki, Hidenori, Nosaki, Kaname, Okuma, Yusuke, Sakamoto, Setsuko, Sone, Takashi, Tanaka, Kentaro, Umemura, Shigeki, Yamanaka, Takeharu, Amano, Shinsuke, Hasegawa, Kazuo, Morita, Satoshi, Nakajima, Kazuko, Maemondo, Makoto, Seto, Takashi, Yamamoto, Nobuyuki

Volltext

The Role of Radiotherapy in the Treatment of Small-Cell Lung Cancer von Nosaki, Kaname, Seto, Takashi

Volltext

Plerixafor stem cell mobilization in Japanese children: A post‐marketing study von Goto, Hiroaki, Kanamori, Rie, Nishina, Satoshi, Seto, Takashi

Volltext

Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort von Okamoto, Isamu, Morita, Satoshi, Tashiro, Naoki, Imamura, Fumio, Inoue, Akira, Seto, Takashi, Yamamoto, Nobuyuki, Ohe, Yuichiro, Nakagawa, Kazuhiko, Fukuoka, Masahiro

Volltext

Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG060... von Goto, Koichi, Dr, Ohe, Yuichiro, MD, Shibata, Taro, MSc, Seto, Takashi, MD, Takahashi, Toshiaki, MD, Nakagawa, Kazuhiko, Prof, Tanaka, Hiroshi, MD, Takeda, Koji, MD, Nishio, Makoto, MD, Mori, Kiyoshi, MD, Satouchi, Miyako, MD, Hida, Toyoaki, MD, Yoshimura, Naruo, MD, Kozuki, Toshiyuki, MD, Imamura, Fumio, MD, Kiura, Katsuyuki, Prof, Okamoto, Hiroaki, MD, Sawa, Toshiyuki, MD, Tamura, Tomohide, MD

Volltext

Capmatinib in Japanese patients with MET exon 14 skipping–mutated or MET‐amplified advanced NSCLC: GEOMETRY mono‐1 study von Seto, Takashi, Ohashi, Kadoaki, Sugawara, Shunichi, Nishio, Makoto, Takeda, Masayuki, Aoe, Keisuke, Moizumi, Sanae, Nomura, Satoshi, Tajima, Takeshi, Hida, Toyoaki

Volltext

Phase II study of ceritinib in alectinib‐pretreated patients with anaplastic lymphoma kinase‐rearranged metastatic non‐small‐cell lung cancer in Japan: ASCEND‐9 von Hida, Toyoaki, Seto, Takashi, Horinouchi, Hidehito, Maemondo, Makoto, Takeda, Masayuki, Hotta, Katsuyuki, Hirai, Fumihiko, Kim, Young Hak, Matsumoto, Shingo, Ito, Masayuki, Ayukawa, Koichi, Tokushige, Kota, Yonemura, Masataka, Mitsudomi, Testuya, Nishio, Makoto

Volltext

KEYNOTE‐025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1–positive advanced non–small‐cell lung cancer von Nishio, Makoto, Takahashi, Toshiaki, Yoshioka, Hiroshige, Nakagawa, Kazuhiko, Fukuhara, Tatsuro, Yamada, Kazuhiko, Ichiki, Masao, Tanaka, Hiroshi, Seto, Takashi, Sakai, Hiroshi, Kasahara, Kazuo, Satouchi, Miyako, Han, Shi Rong, Noguchi, Kazuo, Shimamoto, Takashi, Kato, Terufumi

Volltext